Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) announced that CEO Shalabh Gupta, M.D. will participate in two investor events in December 2025: a Piper Sandler 37th Annual Healthcare Conference fireside chat on Dec 3, 2025 at 10:00 a.m. ET and a Noble Capital Markets virtual presentation on Dec 10, 2025 at 10:00 a.m. PT. Live and archived webcasts will be available on the company's Investor Events and Presentations webpage. Investors seeking a 1x1 meeting should contact their Piper Sandler conference representative to schedule.

LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December.

Event: Piper Sandler 37th Annual Healthcare Conference
Type: Fireside chat
Date/Time: Wednesday, December 3, 2025, at 10:00 a.m. ET

Event: Noble Capital Markets Virtual Presentation
Date/Time: Wednesday, December 10, 2025, at 10:00 a.m. PT

A link to the live and archived Piper Sandler webcast, as well as an archived link of the Noble presentation, may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your Piper Sandler conference representative.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Investor Contact:

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:

Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com

SOURCE: Unicycive Therapeutics, Inc.

FAQ

When will Unicycive (UNCY) present at the Piper Sandler conference in December 2025?

Unicycive CEO will appear in a fireside chat on Dec 3, 2025 at 10:00 a.m. ET.

How can investors watch Unicycive (UNCY) presentations from the December 2025 events?

Live and archived webcasts will be available on Unicycive's Investor Events and Presentations webpage.

When is Unicycive's (UNCY) Noble Capital Markets virtual presentation in December 2025?

The Noble virtual presentation is scheduled for Dec 10, 2025 at 10:00 a.m. PT.

How do I schedule a 1x1 meeting with Unicycive (UNCY) management at Piper Sandler?

To schedule a 1x1, contact your Piper Sandler conference representative as directed in the company's announcement.

Will the Unicycive (UNCY) Piper Sandler session be archived for later viewing?

Yes; a live and archived webcast of the Piper Sandler session will be posted on the company's Investor Events page.